Check out the companies making headlines before the bell. ImmunityBio — The biotech company rallied 22%, adding to a 30% rally in the previous session that was sparked by strong guidance for its bladder cancer drug Anktiva. ImmunityBio expects full-year revenue for the drug to jump 700%. Coupang — Shares rose more than 3% after Deutsche Bank upgraded the Korean retail giant to buy, saying most of the regulatory uncertainty has been priced in. QXO — Shares fell 7% after the roofing products maker announced it would do sell $750 million in common stock. PNC — The bank rose 3% after posting better-than-expected fourth-quarter results and promising guidance. PNC reported revenue of $5.96 billion versus an LSEG consensus estimate of $5.89 billion. Earnings of $4.88 per share also exceeded a forecast of $4.22 per share. PNC also put its total revenue growth by the end of 2026 at roughly 11%, topping the 8.7% estimated by analysts. — CNBC’s Fred Imbert contributed reporting
